It is unclear what he has been doing during his 20 years on the run. However, police had identified more than a dozen aliases he had been using. His police profile described him as a “master navigator, a world traveler and with international connections,” and noted that he had appeared on the television show. America’s Most Wanted.
biotech career
Stat reported that in 2017, Richard Graydon self-published a book titled Genetic risks of cancer: The effects of DNA, genomics and heredity on aging and survival.” The book described Graydon as an oncologist who had served as a medical director in the drug development and biotechnology industry. It had no reviews on Amazon.
In October 2022, Atossa Therapeutics, a Seattle-based biotech, announced that it had hired Richard Graydon as its interim medical director.
“We are privileged to welcome Richard to Atossa, where his deep expertise in CAR-T cell therapy fits well with our current strategic direction as we explore our opportunities in cell therapy,” Steven Quay, CEO of Atossa, said in a statement at the time.
In March, Immix announced the hiring of Graydoncalling him a “board-certified hematologist-oncologist with over 20 years of clinical development experience, most recently at Merck & Co. and Johnson & Johnson, where he led new and complementary new drug applications and biologics license applications for 7 approved drugs, including Darzalex, Carvykti, Keytruda and Imbruvica.” Stat noted that these are some of the best-selling cancer drugs in the world.
“Dr. Graydon received his M.D. and PhD from Stanford University and trained at Harvard Massachusetts General Hospital,” the announcement said.
Stat was unable to verify any of that information and Immix did not respond to requests for comment.
Graydon, also known as Fischer, was arrested July 16 aboard a 56-foot sailboat called The positive side. I was sailing down the East River in New York. “U.S. Marshals and the U.S. Coast Guard intercepted the ship and detained Fischer.”without incident.”
In Immix’s Monday SEC filing announcing Graydon’s firing, the biotech company said that “given his short tenure, management believes there is no material effect on the business.”
